<?xml version="1.0" encoding="UTF-8"?>
<results title="zoonosis">
 <result pre="in the evaluation of favipiravir, an antiâ€�influenza polymerase inhibitor, against" exact="Ebola" post="virus. In this review, we discuss how mathematical modeling"/>
 <result pre="in NHPs were finally used to develop a model of" exact="Ebola" post="pathogenesis integrating the interactions among the virus, the innate"/>
 <result pre="of relevance for future human studies in the context of" exact="Ebola" post="virus, but also for other emerging viral diseases for"/>
 <result pre="years by the large outbreaks of Zika, Chikungunya, Lassa, or" exact="Ebola" post="viruses. Besides these iconic examples, about 200 human pathogenic"/>
 <result pre="in development recently showed encouraging results in animal models against" exact="Ebola" post="virus (EBOV)4, 5 or Zika virus,6 there are no"/>
 <result pre="against a variety of other RNA viruses, in particular Ebola," exact="Lassa fever," post="Marburg, Nipah, and Zika viruses.7, 8, 9 The main"/>
 <result pre="modeling have been instrumental to better understand the immuneâ€�pathogenesis of" exact="Ebola" post="virus disease (EVD) and to optimize the use of"/>
 <result pre="viral clearance. FAVIPIRAVIR IN HUMANS INFECTED WITH EVD The 2013â€&quot;2016" exact="Ebola" post="epidemic has been the largest outbreak of the virus"/>
 <result pre="with the efforts of a global response against the spreading" exact="Ebola" post="epidemic, a European consortium, Reaction! (horizon 2020 grant 666092),"/>
 <result pre="infected intramuscularly with 10 to 1,000 focus forming units with" exact="Ebola" post="virus Gabon 2001 strain, belonging to Zaire ebolavirus species."/>
 <result pre="various emerging viruses. CCHFV, Crimea Congo haemorrhagic fever virus; EBOV," exact="Ebola" post="virus; JUNV, Junin virus; LAV, Lassa fever virus; MARV,"/>
 <result pre="haemorrhagic fever virus; EBOV, Ebola virus; JUNV, Junin virus; LAV," exact="Lassa fever" post="virus; MARV, Marburg virus; RVFV, Rift valley fever virus;"/>
 <result pre="collected in NHPs to elaborate a simplified mathematical model of" exact="Ebola" post="viral dynamics where we assumed no target cell replenishment"/>
 <result pre="in 26 nonhuman primates infected with 1,000 focus forming units" exact="Ebola" post="virus and treated with ascending doses of favipiravir. Left:"/>
 <result pre="a compartment of refractory cells (R). (c) Integrated model of" exact="Ebola" post="virus (EBOV) infection. In addition to compartments presented in"/>
 <result pre="in vitro or in vivo. Combining favipiravir and ribavirin in" exact="Lassa fever" post="Favipiravir was also reported to have antiviral effect on"/>
 <result pre="fever Favipiravir was also reported to have antiviral effect on" exact="Lassa fever" post="virus, providing 100% protection in the lethal NHP model"/>
 <result pre="which prompted its use to treat several patients with severe" exact="Lassa fever" post="virus infection.78 In order to better understand how ribavirin"/>
 <result pre="immunity. Using these models, we consistently estimated an R0 of" exact="Lassa fever" post="virus of about 5â€&quot;6, and an efficacy of favipiravir"/>
 <result pre="at all doses considered, consistent with our results obtained for" exact="Ebola" post="infection in mice.80 Our analyses did not find a"/>
 <result pre="outbreak, the time from symptom onset to admission in the" exact="Ebola" post="treatment centers was between 3 and 5Â days37, 86"/>
 <result pre="the promising effects on favipiravir in the NHP model of" exact="Marburg disease" post="encouraged the implementation of a clinical trial targeting exposed"/>
 <result pre="4Warren, T.K.et alTherapeutic efficacy of the small molecule GSâ€�5734 against" exact="Ebola" post="virus in rhesus monkeys. Nature531, 381â€&quot;385 (2016).26934220 5Warren, T.et"/>
 <result pre="monkeys. Nature531, 381â€&quot;385 (2016).26934220 5Warren, T.et alEfficacy of galidesivir against" exact="Ebola" post="virus disease in rhesus monkeys. Open Forum Infect. Dis.4,"/>
 <result pre="combination with ribavirin in a lethal, immunocompetent mouse model for" exact="Lassa fever." post="J. Infect. Dis.213, 934â€&quot;938 (2016).26531247 10Pushpakom, S.et alDrug repurposing:"/>
 <result pre="(2019).30777297 17Schieffelin, J.S.et alClinical illness and outcomes in patients with" exact="Ebola" post="in Sierra Leone. N. Engl. J. Med.371, 2092â€&quot;2100 (2014).25353969"/>
 <result pre="D.S., Johnson, K.M., Feldmann, H. &amp;amp; Morens, D.M.The pathogenesis of" exact="Ebola" post="virus disease. Annu. Rev. Pathol.12, 387â€&quot;418 (2017).27959626 20Towner, J.S.et"/>
 <result pre="Groseth, A., Callison, J., Takada, A. &amp;amp; Feldmann, H.A novel" exact="Ebola" post="virus expressing luciferase allows for rapid and quantitative testing"/>
 <result pre="of antivirals. Antiviral Res.99, 207â€&quot;213 (2013).23751367 22Caballero, I.S.et alIn vivo" exact="Ebola" post="virus infection leads to a strong innate response in"/>
 <result pre="cells. BMC Genom.17, 707 (2016). 23Baize, S.et alInflammatory responses in" exact="Ebola" post="virusâ€�infected patients. Clin. Exp. Immunol.128, 163â€&quot;168 (2002).11982604 24Wauquier, N.,"/>
 <result pre="P., Padilla, C., Baize, S. &amp;amp; Leroy, E.M.Human fatal Zaire" exact="Ebola" post="virus infection is associated with an aberrant innate immunity"/>
 <result pre="Dis.4, e837 (2010).20957152 25Ruibal, P.et alUnique human immune signature of" exact="Ebola" post="virus disease in Guinea. Nature533, 100â€&quot;104 (2016).27147028 26Vernet, M.â€�A.et"/>
 <result pre="M.â€�A.et alClinical, virological, and biological parameters associated with outcomes of" exact="Ebola" post="virus infection in Macenta, Guinea. JCI Insight2, e88864 (2017).28352651"/>
 <result pre="Insight2, e88864 (2017).28352651 27Reynard, S.et alImmune parameters and outcomes during" exact="Ebola" post="virus disease. JCI Insight4, pii: 125106 (2019). 28McElroy, A.K.et"/>
 <result pre="virus disease. JCI Insight4, pii: 125106 (2019). 28McElroy, A.K.et alHuman" exact="Ebola" post="virus infection results in substantial immune activation. Proc. Natl."/>
 <result pre="for testing or use in patients infected with Ebola. In:" exact="Ebola" post="treatments and interventions. &amp;lt;http://www.who.int/medicines/ebola-treatment/2015_0703TablesofEbolaDrugs.pdf?ua=1&amp;gt; (2015). Accessed September 7, 2015."/>
 <result pre="Results (English version). &amp;lt;https://www.pmda.go.jp/files/000210319.pdf&amp;gt;. 33Oestereich, L.et alSuccessful treatment of advanced" exact="Ebola" post="virus infection with Tâ€�705 (favipiravir) in a small animal"/>
 <result pre="34Smither, S.J.et alPostâ€�exposure efficacy of oral Tâ€�705 (Favipiravir) against inhalational" exact="Ebola" post="virus infection in a mouse model. Antiviral Res.104, 153â€&quot;155"/>
 <result pre="Res.104, 153â€&quot;155 (2014).24462697 35MentrÃ©, F.et alDose regimen of favipiravir for" exact="Ebola" post="virus disease. Lancet Infect Dis.15, 150â€&quot;151 (2015).25435054 36Bouazza, N.et"/>
 <result pre="Lancet385, 603â€&quot;604 (2015). 37Sissoko, D.et alExperimental treatment with favipiravir for" exact="Ebola" post="virus disease (the JIKI Trial): a historically controlled, singleâ€�arm"/>
 <result pre="findings, compassionate use of favipiravir, and outcome in patients with" exact="Ebola" post="virus disease, Guinea, 2015â€�a retrospective observational study. J. Infect."/>
 <result pre="R.W., Mire, C.E., Feldmann, H. &amp;amp; Geisbert, T.W.Postâ€�exposure treatments for" exact="Ebola" post="and Marburg virus infections. Nat. Rev. Drug Discov.17, 413â€&quot;434"/>
 <result pre="(2017).28231247 42Piorkowski, G.et alImplementation of a nonâ€�human primate model of" exact="Ebola" post="disease: Infection of Mauritian cynomolgus macaques and analysis of"/>
 <result pre="of viremia to evaluate the baseline case fatality ratio of" exact="Ebola" post="virus disease and inform treatment studies: a retrospective cohort"/>
 <result pre="Sci.93, 449â€&quot;463 (2017). 47Guedj, J.et alAntiviral efficacy of favipiravir against" exact="Ebola" post="virus: a translational study in cynomolgus macaques. PLoS Med.15,"/>
 <result pre="(2012).22311616 62Hayden, F.G.et alLocal and systemic cytokine responses during experimental" exact="human influenza" post="A virus infection. Relation to symptom formation and host"/>
 <result pre="V.N.et alFavipiravir and ribavirin treatment of epidemiologically linked cases of" exact="Lassa fever." post="Clin. Infect. Dis.65, 855â€&quot;859 (2017).29017278 79Ribeiro, R.M., Laydenâ€�Almer, J.,"/>
 <result pre="S.L.et alEfficacy of favipiravir (Tâ€�705) in nonhuman primates infected with" exact="Ebola" post="virus or Marburg virus. Antiviral Res.151, 97â€&quot;104 (2018).29289666 86Prevail,"/>
 <result pre="Study Team . A randomized, controlled trial of ZMapp for" exact="Ebola" post="virus infection. N. Engl. J. Med.375, 1448 (2016).27732819 87Investigational"/>
 <result pre="1448 (2016).27732819 87Investigational Therapeutics for the Treatment of People with" exact="Ebola" post="Virus Disease â€&quot; Full Text View â€&quot; ClinicalTrials.gov. &amp;lt;https://clinicaltrials.gov/ct2/show/NCT03719586&amp;gt;."/>
 <result pre="â€&quot; ClinicalTrials.gov. &amp;lt;https://clinicaltrials.gov/ct2/show/NCT03719586&amp;gt;. 88Mulangu, S.et alA randomized, controlled trial of" exact="Ebola" post="virus disease therapeutics. N. Engl. J. Med.381, 2293â€&quot;2303 (2019).31774950"/>
 <result pre="90Henaoâ€�Restrepo, A.M.et alEfficacy and effectiveness of an rVSVâ€�vectored vaccine expressing" exact="Ebola" post="surface glycoprotein: interim results from the Guinea ring vaccination"/>
 <result pre="A.et alVSVâ€�EBOV rapidly protects macaques against infection with the 2014/15" exact="Ebola" post="virus outbreak strain. Science349, 739â€&quot;742 (2015).26249231 92Fischer, W.A.et alEbola"/>
</results>
